Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-04-19
DOI
10.1038/srep24572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Nectin-4/Afadin Protein Complex and Intercellular Membrane Pores Contribute to Rapid Spread of Measles Virus in Primary Human Airway Epithelia
- (2015) Brajesh K. Singh et al. JOURNAL OF VIROLOGY
- Overexpression of Cohesion Establishment Factor DSCC1 through E2F in Colorectal Cancer
- (2014) Kiyoshi Yamaguchi et al. PLoS One
- New viruses for cancer therapy: meeting clinical needs
- (2013) Tanner S. Miest et al. NATURE REVIEWS MICROBIOLOGY
- A role for PVRL4-driven cell–cell interactions in tumorigenesis
- (2013) Natalya N Pavlova et al. eLife
- High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS, BRAF, PIK3CA, and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues
- (2012) Jasmin Teresa Ney et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment
- (2012) T Sugiyama et al. GENE THERAPY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies
- (2012) Md. Zeyaullah et al. PATHOLOGY & ONCOLOGY RESEARCH
- Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus
- (2011) Ryan S. Noyce et al. PLoS Pathogens
- Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum
- (2010) Melissa S. DeRycke et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
- (2009) A. Takano et al. CANCER RESEARCH
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines
- (2008) Y TERAOMUTO et al. ANTIVIRAL RESEARCH
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search